Two Executive Campus
2370 State Route 70
Suite 314
Cherry Hill, NJ 08002
Phone: 856-795-6026
Fax: 856.795.4911

In This Section:



Search Our Site:

From Our Newsletters:


June 2017 | Issue 86 Background Constellis Group,  Inc. is a private security firm.  In December 2013, the Company formed an Employee Stock Ownership Plan (“ESOP”), which purchased 100% of Constellis’s voting stock.  Wilmington Trust NA was named Trustee of the ESOP.  Less than a year after the ESOP was created, the ESOP sold all […] More...


March 2017 | Issue 85 Introduction Richard and Steven Parker are brothers who ran a flower business in Scotch Plains, New Jersey.  Richard is the President of Parker Interior Plantscapes (“PIP”), which installs and services plants and flowers in commercial settings.  Steven is the President of Parker Wholesale Florists (“PWF”), which is a garden center.  […] More...

Dell Appraisal Spawns a Multitude of Valuation Approaches

February 2017 | Issue 84 Introduction A Delaware Chancery appraisal case involving computer company Dell Inc. gave rise to a multitude of valuation measurements.  It is instructive to see how the court sorted through them in coming up with its final appraisal conclusion.  The case is In re Appraisal of Dell Inc., 2016 Del. Ch. LEXIS […] More...

Join Our Mailing List...

View our Library...



Life Science Companies Valuations

Many life sciences companies, particularly early-stage firms, share certain characteristics which come into play when one is valuing their stock. Perhaps this can be best illustrated by contrasting some of the value drivers of, say, an early-stage biotech entity with those of a garden variety manufacturing firm.

  • The manufacturing company has a historical sales stream; the biotech company has only a future sales stream.
  • The manufacturing company has a history of profits; the biotech company has a history of losses.
  • The manufacturer has many paying customers; the biotech firm relies on Medicare and other third party payers.
  • The manufacturing company has a plant; the biotech firm has a manufacturing licensing agreement.
  • The manufacturer may or may not rely on patent protection; to the biotech firm, patents are critical.

Looking at the Future Outcomes
The appraiser who is valuing a start-up life sciences company often makes use of a “scenario based” valuation analysis in order to determine the value of the company at a certain moment in time. This involves the preparation of cash flow projections under different possible alternative outcomes. The likelihood or probability of various outcomes is considered. The end point of this analysis is the calculation of an expected net present value of the future cash flows of the company.

Complex Capital Structures
Early-stage companies, because of the history of their financing, often have complex, “legacy,” capital structures. It’s not uncommon for a company to have several layers of preferred stock outstanding. There are a number of valuation approaches that can be undertaken to value the individual stock issues of a company with a complex capital structure. Further details can be found here.

Start-ups Often Make Use of Stock Options
Because of the need to attract high-skilled employees at a time when cash is in short supply, life science start-up companies will often make generous use of employee stock options in their compensation programs.

For both accounting (FAS 123R) and tax (Sec. 409a) reasons, it’s important that these options be valued accurately, and in a manner that will withstand scrutiny should the valuation later be challenged by the company’s auditors, by the IRS or by the SEC. The best way to accomplish this is to have a valuation performed contemporaneously with the issuance of the options, by a party who is independent, and is qualified by skill and experience to perform the valuation.

Our firm has had extensive experience performing valuations of companies in the field of life sciences. We would be happy to be of service should you have a need of valuation advice.